Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 3.4% during the 3rd quarter, Holdings Channel reports. The fund owned 6,695 shares of the life sciences company’s stock after selling 235 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings in Illumina were worth $864,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in Illumina by 426.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock valued at $2,123,000 after acquiring an additional 12,521 shares during the period. Jupiter Asset Management Ltd. purchased a new stake in Illumina during the first quarter worth about $4,527,000. US Bancorp DE boosted its holdings in Illumina by 33.9% during the first quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after buying an additional 8,001 shares in the last quarter. Cetera Advisors LLC acquired a new position in Illumina during the first quarter worth about $610,000. Finally, Weybosset Research & Management LLC increased its holdings in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 1.9 %

Shares of ILMN opened at $150.50 on Tuesday. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $155.37. The company’s fifty day moving average is $136.39 and its two-hundred day moving average is $122.65. The firm has a market cap of $23.97 billion, a PE ratio of -7.86 and a beta of 1.13. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 earnings per share. Analysts forecast that Illumina, Inc. will post 3.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Leerink Partners upped their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada reissued an “outperform” rating and issued a $252.00 target price on shares of Illumina in a report on Thursday, October 10th. UBS Group lifted their price target on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average target price of $157.09.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.